SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Marks JE, Phillips JL, Menck HR. The National Cancer Data Base report on the relationship of race and national origin to the histology of nasopharyngeal carcinoma. Cancer. 1998; 83: 582588.
  • 2
    Ayan I, Kaytan E, Ayan N. Childhood nasopharyngeal carcinoma: from biology to treatment. Lancet Oncol. 2003; 4: 1321.
  • 3
    Greene MH, Fraumeni JF, Hoover R. Nasopharyngeal cancer among young people in the United States: racial variations by cell type. J Natl Cancer Inst. 1977; 58: 12671270.
  • 4
    Pao WJ, Hustu HO, Douglass EC, Beckford NS, Kun LE. Pediatric nasopharyngeal carcinoma: long term follow-up of 29 patients. Int J Radiat Oncol Biol Phys. 1989; 17: 299305.
  • 5
    Ayan I, Altun M. Nasopharyngeal carcinoma in children: retrospective review of 50 patients. Int J Radiat Oncol Biol Phys. 1996; 35: 485492.
  • 6
    Ghim TT, Briones M, Mason P, et al. Effective adjuvant chemotherapy for advanced nasopharyngeal carcinoma in children: a final update of a long-term prospective study in a single institution. J Pediatr Hematol Oncol. 1998; 20: 131135.
  • 7
    Lobo-Sanahuja F, Garcia I, Carranza A, Camacho A. Treatment and outcome of undifferentiated carcinoma of the nasopharynx in childhood: a 13-year experience. Med Pediatr Oncol. 1986; 14: 611.
  • 8
    Roper HP, Essex-Carter A, Marsden HB, Dixon PF, Campbell RHA. Nasopharyngeal carcinoma in children. Pediatr Hematol Oncol. 1986; 3: 143152.
  • 9
    Gasparini M, Lombardi F, Rottoli L, Ballerini E, Morandi F. Combined radiotherapy and chemotherapy in stage T3 and T4 nasopharyngeal carcinoma in children. J Clin Oncol. 1988; 6: 491494.
  • 10
    Arush MW, Stein ME, Bosenblatt E, et al. Advanced nasopharyngeal carcinoma in the young: the Northern Israel oncology center experience, 1973-1991. Pediatr Hematol Oncol. 1995; 12: 271276.
  • 11
    Werner-Wasik M, Winkler P, Uri A, et al. Nasopharyngeal carcinoma in children. Med Pediatr Oncol. 1996; 26: 352358.
  • 12
    Strojan P, Benedik MD, Kragelj R, et al. Combined radiation and chemotherapy for advanced undifferentiated nasopharyngeal carcinoma in children. Med Pediatr Oncol. 1997; 28: 366369.
  • 13
    Ingersoll L, Woo SY, Donaldson S, et al. Nasopharyngeal carcinoma in the young: a combined M.D. Anderson and Stanford experience. Int J Radiat Oncol Biol Phys. 1990; 19: 881887.
  • 14
    Berberoglu S, Ilhan I, Cetindag F, Sunter O. Nasopharyngeal carcinoma in Turkish children: review of 33 cases. Pediatr Hematol Oncol. 2001; 18: 309315.
  • 15
    Lee AWM, Poon YF, Foo W, et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys. 1992; 23: 261270.
  • 16
    Perez CA, Devineni VR, Marcial-Vega V, Marks JE, Simpson JR, Kucik N. Carcinoma of the nasopharynx: factors affecting prognosis. Int J Radiat Oncol Biol Phys. 1992; 23: 271280.
  • 17
    Sanguineti G, Geara FB, Garden AS, et al. Carcinoma of the nasopharynx treated by radiotherapy alone: determinants of local and regional control. Int J Radiat Oncol Biol Phys. 1997; 37: 985996.
  • 18
    Decker DA, Drelichman A, Al-Sarraf M. Chemotherapy for nasopharyngeal carcinoma: a ten-year experience. Cancer. 1983; 52: 602605.
  • 19
    Al-Sarraf M. Chemotherapeutic management of head and neck cancer. Cancer Metast Rev. 1987; 6: 191198.
  • 20
    Chan ATC, Teo PML, Leung TWT, Johnson PJ. The role of chemotherapy in the management of nasopharyngeal carcinoma. Cancer. 1998; 82: 10031012.
  • 21
    Au E, Ang PT. A phase II trial of 5-fluorouracil and cisplatinum in recurrent or metastatic nasopharyngeal carcinoma. Ann Oncol. 1994; 5: 8789.
  • 22
    Chi KH, Chan WK, Cooper DL, Yen SH, Lin CZ, Chen KY. A phase II study of outpatient chemotherapy with cisplatin, 5-fluorouracil and leucovorin in nasopharyngeal carcinoma. Cancer. 1994; 73: 247252.
  • 23
    Gebbia V, Zerillo G, Restivo G, et al. Chemotherapeutic treatment of recurrent and/or metastatic nasopharyngeal carcinoma. A retrospective analysis of 40 cases. Br J Cancer. 1993; 68: 191194.
  • 24
    Huang SC, Lui LT, Lynn TS. Nasopharyngeal cancer study III. A review of 1206 patients treated with combined modalities. Int J Radiat Oncol Biol Phys. 1985; 11: 17891793.
  • 25
    Douglass EC, Fontanesi J, Ribeiro RC, Hawkins E. Improved long-term disease-free survival in nasopharyngeal carcinoma (NPC) in childhood and adolescence: a multi-institution treatment protocol [abstract]. Proc Am Soc Clin Oncol. 1996; 15: A1470.
  • 26
    BeahrsOH, HensonDE, HutterRVP, KennedyBJ, editors. Manual for staging of cancer. 4th edition. Philadelphia: J.B.Lippincott, 1992: 3338.
  • 27
    Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457481.
  • 28
    Peto P, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II, analysis and examples. Br J Cancer. 1977; 35: 139.
  • 29
    Mertens R, Granzen B, Lassay L, Gademann G, Hess CF, Heimann G. Nasopharyngeal carcinoma in childhood and adolescence: concept and preliminary results of the cooperative GPOH study NPC-91. Cancer. 1997; 80: 951959.
  • 30
    Tsukuda M, Sawaki S, Yanoma S. Suppressed cellular immunity in patients with nasopharyngeal carcinoma. J Cancer Res Clin Oncol. 1993; 120: 115118.
  • 31
    Treuner J, Niethammer D, Dannecker G, Hagmann R, Neef V, Hofschneider PH. Successful treatment of nasopharyngeal carcinoma with interferon. Lancet. 1980; 12: 817818.
  • 32
    Chan ATC, Teo PML, Leung TWT, et al. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 1995; 33: 569577.
  • 33
    International Nasopharynx Cancer Study Group: VUMCA I Trial. Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV (≥ N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. Int J Radiat Oncol Biol Phys. 1996; 35: 463469.
  • 34
    Ma J, Mai H-Q, Hong M-H, et al. Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. J Clin Oncol. 2001; 19: 13501357.
  • 35
    Chua DTT, Sham JST, Choy D, et al. Preliminary report of the Asian-Oceanian Clinical Oncology Association randomized trial comparing cisplatin and epirubicin followed by radiotherapy versus radiotherapy alone in the treatment of patients with locoregionally advanced nasopharyngeal carcinoma. Cancer. 1998; 83: 22702283.
  • 36
    Hong S, Wu H-G, Chie EK, et al. Neoadjuvant chemotherapy and radiation therapy compared with radiation therapy alone in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 1999; 45: 901905.
  • 37
    Dewit L. Combined treatment of radium and cis-diamminedichloroplatinum (II): a review of experimental and clinical data. Int J Radiat Oncol Biol Phys. 1987; 13: 403426.
  • 38
    Wolden SL, Zelefsky MJ, Kraus DH, et al. Accelerated concomitant boost radiotherapy and chemotherapy for advanced nasopharyngeal carcinoma. J Clin Oncol. 2001; 19: 11051110.
  • 39
    Cheng SH, Jian JJ-M, Tsai SYC, et al. Long-term survival of nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy. Int J Radiat Oncol Biol Phys. 2000; 48: 13231330.
  • 40
    Rischin D, Corry J, Smith J, Stewart J, Hughes P, Peters L. Excellent disease control and survival in patients with advanced nasopharyngeal cancer treated with chemoradiation. J Clin Oncol. 2002; 20: 18451852.
  • 41
    Al-Sarraf M, LeBlanc M, Giri PGS, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. J Clin Oncol. 1998; 16: 13101317.
  • 42
    Chan ATC, Teo PML, Ngan RK, et al. Concurrent chemotherapy-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: progression-free survival analysis of a phase III randomized trial. J Clin Oncol. 2002; 20: 20382044.
  • 43
    Danenberg PV, Danenberg KD. Effect of 5,10-methylenetetrahydrofolate and the dissociation of 5-fluorodeoxyuridylate binding of human thymidylate synthetase: evidence for an ordered mechanism. Biochemistry. 1978; 17: 40184024.
  • 44
    Evans RM, Laskin JD, Hakala MT. Assessment of growth-limiting events caused by 5-fluorouracil in mouse cells and in human cells. Cancer Res. 1980; 40: 41134122.
  • 45
    Mini E, Trave F, Rustum YM, Bertino JR. Enhancement of the antitumor effects of 5-fluorouracil by folinic acid. Pharmacol Ther. 1990; 47: 119.
  • 46
    Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol. 1992; 10: 896903.
  • 47
    Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol. 2000; 18: 33393345.
  • 48
    Lee N, Xia P, Quivey JM, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys. 2002; 53: 1222.
  • 49
    Braaksma M, Levendag P. Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: subcutaneous amifostine and computed tomography-based target definition. Semin Oncol. 2002; 29( Suppl. 19): 6370.
  • 50
    Hensley ML, Schuchter LM, Lindley C, et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol. 1999; 17: 33333355.
  • 51
    Lo YMD, Chay LYS, Lo K-W, et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res. 1999; 59: 11881191.
  • 52
    Lo YMD, Leung S-F, Chan LYS, et al. Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. Cancer Res. 2000; 60: 23512355.
  • 53
    Lo YMD, Chan LYS, Chan ATC, et al. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. Cancer Res. 1999; 59: 54525455.
  • 54
    Lo YMD, Chan ATC, Chan LYS, et al. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res. 2000; 60: 68786881.
  • 55
    Lin J-C, Wang W-Y, Chen KY, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma. N Engl J Med. 2004; 350: 24612470.